The company, founded in 1997, has a strong partnership with Loma Linda University Medical Center (LLUMC) and has developed advanced proprietary products based on discoveries made by LLUMC researchers. Their lead drug candidate, E-7869 (MPC-7869), shows promise in treating prostate and colon cancer. Encore Pharmaceuticals is also exploring the potential of a tocopherol compound for its anti-cancer, anti-hypertensive, and anti-oxidant properties.